Tout sur REDOLA

Les études évaluant l'efficacité et la sécurité d'emploi du 2DR (DTG/3TC) en conditions de vie de réelle sont de plus en plus nombreuses au fil des congrès internationaux mais ce qui distingue l'étude espagnole REDOLA, présentée à Glasgow, est la proportion importante, 71,4%, de patients naïfs mis sous traitement sans attendre le retour des résultats des tests d'évaluation des mutations de résistance.

Partner content ViiV Healthcare

Lire l'article

Live from

Lire les articles

Online e-learning

Real-world treatment adherence and strict inclusion criteria used during RCTs can lead to several patient groups being underrepresented. Therefore, real-world data on DTG-based 2DRs are highly needed to be able to evaluate virologic and safety outcomes in these underrepresented patient groups.In this webinar, Dr. Nasreddine highlighted the outcomes of the BREACH DTG-based 2DR cohort, a retrospective, observational, multicenter study (n=10).Subsequently Prof. De Wit, Chair of the Belgian HIV Research Consortium BREACH, gave his clinical implications of these cohort data.Finally, Dr. De Scheerder provided a comprehensive overview of the real-world DTG/3TC data that are currently available beyond Belgium.

Take the course